Austerity takes off gloss from Basilea's Toctino forecasts
This article was originally published in Scrip
Basilea Pharmaceutica reduced its 2011 sales forecast for its hand eczema treatment Toctino (alitretinoin) from around CHF40 million to CHF32-34 million. The company's chief commercial officer, Hans Christian Rohde, said volume growth for the full year for the once-daily retinoid capsule, Basilea's only marketed product, would be around 30%. "It will take longer than anticipated to get to cruising altitude," he said.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.